泰利克斯制药 TLX

Richard Valeix serves as our Chief Executive Officer, Telix Therapeutics. Mr. Valeix leads the Company's therapeutic pipeline commercialization and business development. He has more than 20 years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas. Previously, Richard worked at Advanced Accelerator Applications (AAA), a Novartis Company (from January 2014 to April 2021) where he served in the roles of General Manager for France, Switzerland, Belgium, Netherlands and Luxembourg, and Global Head of Marketing and Sales.

David Cade has served as our Group Chief Medical Officer since January 2024. Prior to transitioning to this role, he was the Chief Executive Officer of our Asia Pacific operations from May 2021 to December 2023 and our Chief Business Officer and Head of Investor Relations from October 2019 to April 2021. Previously, he served as Chief Medical Officer at Sirtex Medical Limited from January 2007 to September 2017 and Chief Medical Officer at Cochlear Limited from October 2017 to September 2019. Dr. Cade received a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Monash Medical School and a Master of Business Administration (MBA) from Melbourne Business School and ESADE Business and Law School Barcelona. He is also a Graduate of the Australian Institute of Company Directors.

Mark Nelson has served as a Non-Executive Director since September 2017 and as Interim Chair since February 3, 2026. Dr. Nelson has served as Chairman of the Caledonia Investments Group since January 2012, and as a Director of The Caledonia Foundation since August 2002. He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group from February 1992 to January 2012. He has also served as Director of Kaldor Public Art Projects since October 2005, Governor of the Florey Neurosciences Institute since October 2007, Director of the Mindgardens Neuroscience Network since February 2018 and Chairman of Art Exhibitions Australia since 2019. Dr. Nelson received his B.Sc. from the University of Melbourne, his M.Phil from the University of Cambridge and his Ph.D. from the University of Melbourne.

Marie McDonald has served as a Non-Executive Director since March 2025. Ms. McDonald serves as a Non-Executive Director of Nanosonics Limited (since October 2016), Walter and Eliza Hall Institute of Medical Research (since October 2016) and Nufarm Limited (since March 2017), and served as a Non-Executive Director of CSL Limited between August 2013 and October 2025. Ms McDonald practised as a commercial lawyer, specializing in mergers and acquisitions and corporate governance, at Ashurst Australia (previously Blake Dawson Waldron) from 1984 to 2014. She was a member of the Australian Takeovers Panel from 2001 to 2010, and was also Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012-2013), having previously been a deputy chair. Ms. McDonald received her BSc (Hons) and LLB (Hons) from the University of Melbourne

Mary Jessel serves as our Group Chief of Clinical Affairs. Dr. Jessel has over 15 years of pharmaceutical, biotechnology and drug development experience and has proven expertise in building effective Medical Affairs infrastructure, launch and product lifecycle strategies. She is passionate about innovation that improves unmet medical need and enhancing the accessibility and comprehensibility of complex medical and scientific information. Dr. Jessel has led successful product launches at Ionis Pharmaceuticals and Akcea, drug development at Alcamena Stem Cell Therapeutics, and drug development research at the University of California, San Francisco in leukodystrophies. She holds a PhD in Neuroscience from the University of Michigan and a MBA from Portland State University.

Mr. Raphael Ortiz serves as our Chief Executive Officer, Telix International. Mr. Ortiz leads the rest of world commercial operations for Europe, Middle East and Africa (EMEA), Asia Pacific (APAC) and Latin America regions. He joined Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia. Prior to joining Telix, he worked at Advanced Accelerator Applications, a Novartis Company, and most recently in the role of Asia-Pacific Cluster Head, setting up the radioligand therapy operations in the region

Genevieve Ryan has served as our Company Secretary since December 2022. Ms. Ryan has over 20 years' experience in legal and governance roles, including with ASX-200 companies. Previously, she was General Counsel - Governance, Corporate and Commercial at Orora Limited. Ms. Ryan was also previously Senior Legal Counsel and Alternate Company Secretary at Australian Pharmaceutical Industries Limited (acquired by Wesfarmers Limited). Ms Ryan began her career as a lawyer with law firm Ashurst. She holds a Bachelor of Laws (Honors) and Bachelor of Science (Honors). Ms Ryan is a fellow of the Governance Institute of Australia and a graduate member of the Australian Institute of Company Directors.

Meredith Crowe serves as our Senior Vice President, People & Culture. Ms. Crowe has been with Telix since October 2021 and has more than 10 years experience driving people strategy in health and biotech, most recently in organizational development at the Peter MacCallum Cancer Centre. Ms. Crowe holds a Masters of Design from Victoria University and is an IECL Certified Executive Coach